Clene Inc. (CLNN)

$2.8

-0.01 (-0.36%)
Rating:
Recommendation:
-
Symbol CLNN
Price $2.8
Beta 0.453
Volume Avg. 1.18M
Market Cap 177.806M
Shares () -
52 Week Range 1.93-7.98
1y Target Est -
DCF Unlevered CLNN DCF ->
DCF Levered CLNN LDCF ->
ROE 676.23% Strong Buy
ROA 74.91% Strong Buy
Operating Margin -
Debt / Equity -8011.55% Strong Sell
P/E 11.67 Strong Buy
P/B -0.31 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CLNN news


Healthcare
Biotechnology
NASDAQ Capital Market

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.